FDA Approves New Oral Cholesterol Drug Lipfendra

Adults with high cholesterol have a new daily tablet option to help lower their LDL levels.

Updated on Oct. 30, 2026 in Heart Disease

Isometric editorial illustration of a stylized liver organ, with abstract molecular structures showing receptor binding, representing cholesterol management. — The FDA approved Lipfendra, an oral medication for adults, to assist in lowering LDL cholesterol levels alongside diet and exercise. AI Illustration. Upload story photo >

Live Poll

Do you trust that new pharmaceutical cholesterol treatments represent a significant improvement for your health?

On July 17, 2026, the FDA approved Lipfendra, an oral tablet containing the active ingredient enlicitide, to lower LDL cholesterol in adults. This new medication is intended to be used alongside diet and exercise for individuals with high cholesterol, including those with heterozygous familial hypercholesterolemia.

Why it matters

Lipfendra offers a new treatment option for managing cholesterol levels by helping the liver clear LDL from the blood more effectively. For patients, this represents a new clinical tool, though current evidence does not yet confirm if the drug reduces the risk of heart attacks or strokes.

In 24-week clinical trials, Lipfendra demonstrated an LDL cholesterol reduction of approximately 56% to 59% compared with placebo. These findings are limited to the 24-week study period and do not yet establish clinical outcomes regarding heart disease prevention.

The players

FDA

The federal agency responsible for protecting public health by regulating the safety and efficacy of pharmaceuticals.

The details

Lipfendra works by blocking the protein PCSK9, which naturally reduces the number of LDL receptors on liver cells. By inhibiting this protein, the drug increases the availability of these receptors, allowing the liver to clear more LDL cholesterol from the bloodstream. Patients take a single 20 mg tablet once daily on an empty stomach with water, black coffee, or plain tea.

July 17, 2026: FDA approved Lipfendra.
24 weeks: Duration of the primary clinical trial assessment period.

Health Landscape

Lipfendra represents a shift in the PCSK9 inhibitor class, which has historically relied on injectable delivery methods. This development provides a new oral option for patients, though it follows a well-established scientific focus on targeting PCSK9 to manage lipid levels.

If you are managing high cholesterol, this development is a potential topic for your next conversation with your doctor to see if an oral PCSK9 inhibitor fits your treatment plan. Because the drug must be taken on an empty stomach in the morning, discuss how this fits into your daily routine.

The takeaway

Lipfendra provides a new oral daily option for lowering LDL cholesterol in adults. When discussing this with a physician, confirm your eligibility for the medication and ask about the current trial limitations regarding cardiovascular outcomes.